HLS Therapeutics (TSX:HLS) Debt-to-Asset : 0.33 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:HLS HLS Therapeutics Inc TSX:HLS
68 GF Score
Price C$3.75
GF Value C$4.36
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Debt-to-Asset?

HLS Therapeutics TSX:HLS -4.82% 68 Debt-to-Asset is 0.33 as of Jun. 2026. GuruFocus rates TSX:HLS with a GF Score™ of 68/100 and a GF Value™ of C$4.36 (Modestly Undervalued). The stock has 4 warning signs investors should review.

HLS Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was C$6.45 Mil. HLS Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was C$52.36 Mil. HLS Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was C$180.41 Mil. HLS Therapeutics's debt to asset for the quarter that ended in Jun. 2026 was 0.33.

HLS Therapeutics  (TSX:HLS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

HLS Therapeutics Debt-to-Asset Related Terms

HLS Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for HLS Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics Debt-to-Asset Chart

HLS Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.40 0.42 0.42 0.36

HLS Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.39 0.36 0.34 0.33

TSX:HLS vs ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Debt-to-Asset falls into.


TSX:HLS
68GF Score
HLS Therapeutics Inc TSX:HLS
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HLS Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

HLS Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.645 + 62.084) / 189.721
=0.36

HLS Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.447 + 52.361) / 180.406
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.33 mean?
HLS Therapeutics (TSX:HLS) has a Debt-to-Asset of 0.33 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on HLS Therapeutics and its competitors.
Is HLS Therapeutics' Debt-to-Asset too high?
HLS Therapeutics' current Debt-to-Asset is 0.33. Overall, HLS Therapeutics has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Debt-to-Asset compare to ZTS?
HLS Therapeutics' Debt-to-Asset of 0.33 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current Debt-to-Asset is 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Modestly Undervalued. The stock's GF Value™ is C$4.36, compared to a current price of C$3.75 — trading 14% below its estimated fair value. The current Debt-to-Asset is 0.33. HLS Therapeutics' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Debt-to-Asset is 0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$3.75 is trading 14% below its estimated GF Value™ of C$4.36. GuruFocus considers HLS Therapeutics to be Modestly Undervalued.

Key valuation signals for TSX:HLS:

  • Debt-to-Asset: 0.33
  • GF Value™: C$4.36 vs. price of C$3.75 (14% below fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
68GF Score

Get the complete analysis for TSX:HLS

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$3.75
Price
C$4.36
GF Value